Lipodystrophy Syndrome in HIV Infection: What is it, What Causes it and How Can it Be Managed?

Author： Behrens G.M.N.   Stoll M.   Schmidt R.E.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.23, Iss.1, 2000-07, pp. : 57-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Facilitating Adherence to Highly Active Antiretroviral Therapy in Children with HIV Infection: What Are the Issues and What Can Be Done?

By Pontali Emanuele  

Pediatric Drugs, Vol. 7, Iss. 3, 2005-01 ,pp. : 137-149

Adis International

Access to resources Recommend Favorite

Breastfeeding in HIV-Positive Women: What Can be Recommended?

By Slater Mackenzie   Stringer Elizabeth M.   Stringer Jeffrey S.A.  

Pediatric Drugs, Vol. 12, Iss. 1, 2010-02 ,pp. : 1-9

Adis International

Access to resources Recommend Favorite

Preventing MTCT in HIV: what cost in developing countries?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 376, 2002-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Preventing MTCT in HIV: what cost in developing countries?

By  

Inpharma, Vol. 1, Iss. 1352, 2002-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Recurrent Clostridium difficile Infection: What are the Treatment Options?

By >   Verbon Annelies   Kuipers Ernst J.  

Drugs, Vol. 71, Iss. 7, 2011-05 ,pp. : 853-868

Adis International

Access to resources Recommend Favorite